Q79.61 Classical Ehlers-Danlos syndrome

Name of the Condition

• Classical Ehlers-Danlos syndrome

Summary

Classical Ehlers-Danlos syndrome (cEDS) is a hereditary connective tissue disorder characterized by skin hyperextensibility, atrophic scarring, and generalized joint hypermobility. It results from defects in collagen synthesis, particularly affecting types V and I collagen, which are critical for tissue strength and integrity. Clinical manifestations vary in severity, with some individuals experiencing mild symptoms and others facing significant functional limitations or complications.

Causes

cEDS is caused by pathogenic variants in the COL5A1 or COL5A2 genes, which encode for type V collagen. These genetic mutations disrupt collagen production or structure, leading to weakened connective tissues. Inheritance is typically autosomal dominant, meaning a single altered copy of the gene from one parent can cause the condition. Spontaneous mutations may also occur in individuals with no family history.

Risk Factors

• Family history of classical Ehlers-Danlos syndrome or related connective tissue disorders.
• Inherited genetic mutations in COL5A1 or COL5A2.
• Advanced paternal age (in cases of de novo mutations).

Symptoms

• Skin that is hyperextensible, fragile, and prone to tearing or bruising.
• Atrophic (papyraceous) scarring, often following minor trauma.
• Generalized joint hypermobility, leading to frequent dislocations or subluxations.
• Musculoskeletal pain, including chronic joint or muscle discomfort.
• Easy bruising and delayed wound healing.

Diagnosis

Diagnosis is based on clinical evaluation, family history, and genetic testing. Clinical criteria include skin hyperextensibility, atrophic scarring, and generalized joint hypermobility. Molecular genetic testing for COL5A1 or COL5A2 variants confirms the diagnosis. Differential diagnosis may be necessary to exclude other EDS subtypes or overlapping connective tissue disorders.

Treatment Options

Management focuses on symptom relief and complication prevention. Interventions may include:

• Physical therapy to strengthen muscles and stabilize joints.
• Wound care for fragile skin, including protective measures and proper healing techniques.
• Pain management strategies, such as nonsteroidal anti-inflammatory drugs (NSAIDs) or physical modalities.
• Surgical repair of severe joint dislocations or hernias, with caution due to tissue fragility.
• Genetic counseling for affected individuals and their families.

Prognosis and Follow-Up

Prognosis varies depending on symptom severity and complications. Most individuals have a normal lifespan, but chronic pain and joint instability may impact quality of life. Regular follow-up with a multidisciplinary team (e.g., rheumatology, dermatology, genetics) is recommended to monitor for complications and adjust management as needed.

Complications

• Chronic joint pain or instability, potentially leading to arthritis.
• Skin complications, such as severe scarring or delayed healing.
• Vascular issues, including easy bruising or, rarely, organ rupture.
• Gastrointestinal problems, such as hernias or diverticula.
• Increased risk of surgical complications due to tissue fragility.

Lifestyle & Prevention

• Avoid activities that strain joints or risk skin injury.
• Use protective gear during physical activities to prevent trauma.
• Maintain a healthy weight to reduce joint stress.
• Practice gentle exercise, such as swimming or low-impact stretching, to support joint stability.
• Protect skin from sun exposure and use moisturizers to improve elasticity.

When to Seek Professional Help

Seek medical attention if you experience:

• Sudden or severe joint pain or dislocation.
• Unexplained bruising, skin tears, or slow-healing wounds.
• Signs of organ rupture (e.g., severe abdominal pain, chest pain).
• New or worsening symptoms that affect daily functioning.

Tips for Medical Coders

When coding for classical Ehlers-Danlos syndrome, use ICD-10-CM code Q79.61. Ensure documentation supports the diagnosis, including clinical findings (e.g., skin hyperextensibility, atrophic scarring) and genetic testing results if available. Verify that the code is not used for other EDS subtypes, as specificity is critical for accurate reporting.